Last reviewed · How we verify

NCT05802550: CATARACTOMIQUE

Metabo-lipidomics of the Ocular Surface for Cataract Surgery

Completed NA Last updated 13 February 2026
What this trial tests

NA trial testing Ocular Surface Disease Index in Age-related Cataract in 100 participants. Completed in 9 July 2025.

Timeline
4 September 2023
Primary endpoint
9 July 2025
9 July 2025

Quick facts

Lead sponsorUniversity Hospital, Tours
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment100
Start date4 September 2023
Primary completion9 July 2025
Estimated completion9 July 2025
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Tours

Who can join

50 and older, any sex, with Age-related Cataract. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cataract is the world's leading cause of blindness, the treatment of which, exclusively surgical, offers excellent results in terms of visual recovery. It represents the most frequently performed surgery in France with more than 800,000 procedures each year. However, some patients develop postoperative ocular surface disease that can affect final visual acuity and quality of life. For example, dry eye disease, very common in the elderly, can be worsened by cataract surgery. The identification of ocular surface biomarkers predictive of the postoperative risk of ocular surface disease carries the promise of better personalized perioperative care. Conjunctival impression cytology represents a rapid, minimally invasive method of collecting conjunctival cells, which has proven its usefulness in the evaluation of diseases of the ocular surface. The aqueous humor is directly accessible at the beginning of the surgery. An approach combining ultra-high performance liquid chromatography coupled with high-resolution mass spectrometry on the cells of the ocular surface and on the aqueous humor could improve our understanding of the physiopathology of ocular surface disease following cataract surgery. This study will aim to 1) search for prognostic biomarkers of ocular surface disease after cataract surgery using a metabo-lipidomic approach 2) improve our understanding of the pathophysiological mechanisms involved.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Human retinal secretome: A cross-link between mesenchymal and retinal cells.
    Donato L, Scimone C, Alibrandi S, Scalinci SZ, et al · · 2023 · cited 6× · PMID 37545752 · DOI 10.4252/wjsc.v15.i7.665

Verify or expand the search:

Other trials of Ocular Surface Disease Index

Trials testing the same drug.

Other University Hospital, Tours trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05802550.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing